DOJ Asks To Join Wyeth Rapamune Qui Tam Suit

Law360, New York (September 21, 2010, 5:16 PM EDT) -- The U.S. Department of Justice sought permission Tuesday to join a whistleblower suit accusing Wyeth Pharmaceuticals Inc. of illegally marketing kidney transplant drug Rapamune for use in other, unapproved organ transplant operations.

The motion, filed in the U.S. District Court for the Eastern District of Pennsylvania, seeks permission for the federal government to intervene in the qui tam suit "for good cause" with the support of the whistleblowers who brought the action in 2005.

The government's memorandum supporting its efforts was filed under seal.

A representative...
To view the full article, register now.